What is IN8bio's market cap?

IN8bio (INAB) has a market capitalization of $11.4M and trades on NASDAQ.

Who are IN8bio's competitors?

IN8bio's key competitors include Adicet Bio, Inc., Century Therapeutics, Inc., Editas Medicine, Inc., and others. These companies compete in similar markets and product categories.

Who does IN8bio partner with?

IN8bio's notable partners include Emory University, The UAB Research Foundation, Children’s Healthcare of Atlanta, Inc., and others.

Where is IN8bio headquartered?

IN8bio is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2021.

IN8bio

INAB

IN8bio is a clinical-stage biopharmaceutical company specializing in the development of gamma-delta T cell therapies for cancer and autoimmune diseases.

Market cap

$11.41M+54.1%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$0.26Beat by $0.33

Read the full report

Next report

Aug 6, 2026 (In 1 week)

EPS estimate-$0.34

Competitors

By market cap

Pfizer$140.61B+1.7%

Regeneron Pharmaceuticals$69.9B+16.0%

Shattuck Labs, Inc.$672.4M+1,610%

Editas Medicine$411.3M+66.0%

Century Therapeutics$376.9M+584%

Adicet Bio, Inc.$75.3M+21.1%

GT Biopharma$12.0M+75.3%

IN8bio$11.4M+41.0%

By revenue growth

Regeneron Pharmaceuticals+5.9%

Pfizer+1.4%

Shattuck Labs, Inc.-78.3%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Pfizer15.65%+6.3pp

Shattuck Labs, Inc.-4,987.4%-3,454pp

Profile

IN8bio is a clinical-stage biopharmaceutical company specializing in the development of gamma-delta T cell therapies for cancer and autoimmune diseases. The company leverages its proprietary DeltEx platform to engineer and manufacture ex vivo expanded gamma-delta T cells that bridge innate and adaptive immunity. Its core value proposition lies in creating therapies that can distinguish between healthy and diseased tissue while overcoming the limitations of traditional CAR-T and NK cell approaches.

Competitive position

IN8bio is a leading clinical-stage player in the specialized gamma-delta T cell niche, holding a first-mover advantage with the first genetically modified gamma-delta T cell therapy to enter clinical trials.

GeographiesUnited States

Customer segmentsClinical Research Institutions, Specialized Healthcare Providers, Strategic Biopharma Partners

Business modelR&D focused, IP Licensing, Biotechnology Product Development

SuppliersLentiviral vector suppliers, Raw material providers, GMP cell therapy laboratory facilities, Academic licensing partners

CustomersClinical trial sites, Tertiary referral centers, Strategic biopharmaceutical collaborators

CountryUnited States of America

Listed2021

Employees34.0

CEOWilliam T.

SectorHealthcare

IndustryBiotechnology

Websitein8bio.com

FilingsSEC EDGAR

Questions, answered.

What is IN8bio's market cap?: IN8bio (INAB) has a market capitalization of $11.4M and trades on NASDAQ.
Who are IN8bio's competitors?: IN8bio's key competitors include Adicet Bio, Inc., Century Therapeutics, Inc., Editas Medicine, Inc., and others. These companies compete in similar markets and product categories.
Who does IN8bio partner with?: IN8bio's notable partners include Emory University, The UAB Research Foundation, Children’s Healthcare of Atlanta, Inc., and others.
Where is IN8bio headquartered?: IN8bio is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2021.